Alzheimer's Disease: The Challenge of the Second Century

被引：1074

作者：

Holtzman, David M. ^{[1
,2
,3
,4
]}

Morris, John C. ^{[1
,3
,4
,5
]}

Goate, Alison M. ^{[1
,3
,4
,6
]}

机构：

[1] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA

[2] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA

[3] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA

[4] Washington Univ, Sch Med, Knight Alzheimers Dis Res Ctr, St Louis, MO 63110 USA

[5] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA

[6] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA

来源：

SCIENCE TRANSLATIONAL MEDICINE | 2011年 / 3卷 / 77期

关键词：

AMYLOID-PRECURSOR-PROTEIN; MILD COGNITIVE IMPAIRMENT; PAIRED HELICAL FILAMENT; GENOME-WIDE ASSOCIATION; HEREDITARY CEREBRAL-HEMORRHAGE; CEREBROSPINAL-FLUID TAU; CENTRAL-NERVOUS-SYSTEM; A-BETA; APOLIPOPROTEIN-E; MOUSE MODEL;

D O I：

10.1126/scitranslmed.3002369

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Alzheimer's disease (AD) was first described a little more than 100 years ago. It is the most common cause of dementia with an estimated prevalence of 30 million people worldwide, a number that is expected to quadruple in 40 years. There currently is no effective treatment that delays the onset or slows the progression of AD. However, major scientific advances in the areas of genetics, biochemistry, cell biology, and neuroscience over the past 25 years have changed the way we think about AD. This review discusses some of the challenges to translating these basic molecular and cellular discoveries into clinical therapies. Current information suggests that if the disease is detected before the onset of overt symptoms, it is possible that treatments based on knowledge of underlying pathogenesis can and will be effective.

引用

页数：17

共 219 条

[1] Report of the task force on designing clinical trials in early (predementia) AD [J].

Aisen, P. S. ;

Andrieu, S. ;

Sampaio, C. ;

Carrillo, M. ;

Khachaturian, Z. S. ;

Dubois, B. ;

Feldman, H. H. ;

Petersen, R. C. ;

Siemers, E. ;

Doody, R. S. ;

Hendrix, S. B. ;

Grundman, M. ;

Schneider, L. S. ;

Schindler, R. J. ;

Salmon, E. ;

Potter, W. Z. ;

Thomas, R. G. ;

Salmon, D. ;

Donohue, M. ;

Bednar, M. M. ;

Touchon, J. ;

Vellas, B. .

NEUROLOGY, 2011, 76 (03) :280-286

[2] Alzheimer's disease therapeutic research: the path forward [J].

Aisen, Paul S. .

ALZHEIMERS RESEARCH & THERAPY, 2009, 1 (01)

[3]

Alzheimer A., 1907, Allg Zeitschrift Psychiatr, V64, P146, DOI DOI 10.1002/CA.980080612

[4] Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration [J].

Araki, T ;

Sasaki, Y ;

Milbrandt, J .

SCIENCE, 2004, 305 (5686) :1010-1013

[5]

AREOSA SA, 2005, COCHRANE DB SYST REV, V18

[6] Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition [J].

Bales, KR ;

Verina, T ;

Dodel, RC ;

Du, YS ;

Altstiel, L ;

Bender, M ;

Hyslop, P ;

Johnstone, EM ;

Little, SP ;

Cummins, DJ ;

Piccardo, P ;

Ghetti, B ;

Paul, SM .

NATURE GENETICS, 1997, 17 (03) :263-264

[7] Tau-mediated neurodegeneration in Alzheimer's disease and related disorders [J].

Ballatore, Carlo ;

Lee, Virginia M. -Y. ;

Trojanowski, John Q. .

NATURE REVIEWS NEUROSCIENCE, 2007, 8 (09) :663-672

[8] Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].

Bard, F ;

Cannon, C ;

Barbour, R ;

Burke, RL ;

Games, D ;

Grajeda, H ;

Guido, T ;

Hu, K ;

Huang, JP ;

Johnson-Wood, K ;

Khan, K ;

Kholodenko, D ;

Lee, M ;

Lieberburg, I ;

Motter, R ;

Nguyen, M ;

Soriano, F ;

Vasquez, N ;

Weiss, K ;

Welch, B ;

Seubert, P ;

Schenk, D ;

Yednock, T .

NATURE MEDICINE, 2000, 6 (08) :916-919

[9] Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank [J].

Barker, WW ;

Luis, CA ;

Kashuba, A ;

Luis, M ;

Harwood, DG ;

Loewenstein, D ;

Waters, C ;

Jimison, P ;

Shepherd, E ;

Sevush, S ;

Graff-Radford, N ;

Newland, D ;

Todd, M ;

Miller, B ;

Gold, M ;

Heilman, K ;

Doty, L ;

Goodman, I ;

Robinson, B ;

Pearl, G ;

Dickson, D ;

Duara, R .

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2002, 16 (04) :203-212

[10] Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo [J].

Bateman, Randall J. ;

Munsell, Ling Y. ;

Morris, John C. ;

Swarm, Robert ;

Yarasheski, Kevin E. ;

Holtzman, David M. .

NATURE MEDICINE, 2006, 12 (07) :856-861

← 1 2 3 4 5 6 7 8 9 10 →